Drugs
Bremelanotide: First Approval
View on PubMed
VentraSciencesVentraSciencesTrending
A bremelanotide research peptide studied in melanocortin receptor research. For laboratory research use only.
Card fields are hosted by our payment provider, so card numbers are never received or stored by Ventra. Apple Pay, Google Pay and Link are also available at checkout.
Technical specifications
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied in pharmacology and receptor-binding research.
Research applications: Used in melanocortin receptor research.
Peer-reviewed research
Some titles are not reproduced here. Ventra Sciences sells for research use only and does not republish therapeutic indications; open the record on PubMed to read the full citation.
References are provided for qualified researchers as a starting point for literature review. Ventra Sciences makes no claims about the contents of cited works.
This product is intended strictly for in vitro laboratory research by qualified professionals. It is not for human or veterinary use and must not be used in food, drugs, diagnostics, or cosmetics. Ventra Sciences makes no medical claims regarding any compound sold. All purchasers acknowledge they will use this product solely for research purposes.
This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must comply with applicable institutional, local, and federal regulations.
By purchasing from Ventra Sciences, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance.
Exclusive updates and restock alerts, straight to your inbox.
